EUCTR2006-004516-51-DE进行中（未招募）不适用
A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement - Zanolimumab with CHOP in CD4+ non-cutaneous PTCL with nodal involvement
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non-cutaneous peripheral T-cell lymphoma, with nodal involvement, with a CD4
- •positive phenotype confirmed by biopsy that must be performed within 2 months of
- •Screening (node involvement must be accessible and measurable) excluding ALK+
- •2. Subjects must be eligible for the CHOP chemotherapy regimen.
- •3. Subjects may have had no more than one previous chemotherapy, excluding
- •anthracyclines, and must have been in remission for at least one year.
- •4. Measurable disease according to the Standardized Response Criteria for NHL
- •5. Age = 18 years.
- •6. Has read and understands and has signed the informed consent (or has a legally
- •acceptable representative who has signed on their behalf).
- •7. Women of childbearing potential (i.e all female patients after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive) must have a negative pregancy test at screening.
- •8. Women of childbearing potential and males with female partners of childbearing potential must be willing to avoid pregancy by using an adequate method of contraception (defined as two barrier methods, or one barrier method with a spermicide, or intrauterine device or use of the oral female contraceptive) for 4 weeks prior to and during the study and 8 weeks after the end of the last 3 week cycle of CHOP).
- •9. ECOG performance status = 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known or suspected hypersensitivity to CHOP or components of the IMP.
- •2. Known infection with HIV, unresolved hepatitis C (HCV RNA+ in plasma) or
- •hepatitis B (HBV DNA+, HBs Ag+, HBc Ag+), signs and symptoms of transmissible
- •spongiform encepalopathy.
- •3. Other concurrent or previous malignancies within the past 5 years, except adequately treated in situ carcinoma of the uterine cervix or basal cell carcinoma.
- •4. Significant concurrent, uncontrolled or active medical condition including, but not
- •limited to acute or chronic infectious disease requiring systemic medication, renal,
- •hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological,
- •cerebral or psychiatric disease.
- •5. Known or clinical suspicion for CNS involvement of the PTCL with nodal
- •involvement.
- •6. Severe bone marrow impairment as evidenced by Hemoglobin (Hb) < 9.0 g/dL ,
- •absolute neutrophil count (ANC) < 0.5x 109/l, platelets < 20 x 109/l at Screening.
- •7. Subjects having received extensive radiotherapy (involving = 30% of bone marrow)
- •within the last 2 years.
- •8. Renal impairment as evidenced by serum creatinine > 1.5 x upper limit of normal
- •(ULN), and/or calculated creatinine clearance < 60 ml/min at Screening.
- •9. Liver function abnormality as defined by total bilirubin > 1.5 ULN and/or AST/ALT >
- •2.5x ULN or for subjects with liver involvement AST/ALT > 5x ULN.
- •10. INR > 1.5 x ULN at Screening.
- •11. Breast-feeding women or women with a positive pregnancy test at Screening
- •12. Any immunosuppressive or cytotoxic drugs within 3 months from Screening (e.g.
- •drugs interfering with the functions of T cells, IL-2, etc.)
- •13. Prior treatment with anti-CD4 monoclonal antibodies within one year prior to
研究者
相似试验
进行中（未招募）
1 期
A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement - Zanolimumab with CHOP in CD4+ non-cutaneous PTCL with nodal involvementCD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvementMedDRA version: 8.1Level: LLTClassification code 10034624Term: Peripheral T-cell lymphoma unspecified NOSEUCTR2006-004516-51-NLGenmab A/S24
进行中（未招募）
不适用
A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement - Zanolimumab with CHOP in CD4+ non-cutaneous PTCL with nodal involvmentCD4 positive non cutaneous peripheral T-Cell lymphoma with nodal involvementMedDRA version: 9.1Level: LLTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedEUCTR2006-004516-51-ITSERONO INTERNATIONAL SA24
进行中（未招募）
1 期
Pharmacokinetic and safety of serelaxin when added to standard of care in pediatric patients hospitalized with acute heart failureEUCTR2013-002847-28-DEovartis Pharma Services AG30
进行中（未招募）
1 期
A research study to look at the safety, effectiveness and the effects on the body of a new drug, SBC-102, in children with growth problems caused by a deficiency in the enzyme that breaks down fatsEUCTR2011-000032-28-GBSynageva Biopharma Corp.10
进行中（未招募）
1 期
A research study to look at the safety, effectiveness and the effects on the body of a new drug, SBC-102, in children with growth problems caused by a deficiency in the enzyme that breaks down fatsGrowth failure in children due to lysosomal acid lipase deficiency (Wolman disease).MedDRA version: 13.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: HLGTClassification code 10021605Term: Inborn errors of metabolismSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000032-28-FRSynageva Biopharma Corp.8